Mount Sinai Researchers Receive Major NIH Award for Autism Genetics Research
$7million grant extends Autism Sequencing Consortium through 2022 to collect genetic data of more than 50,000 individuals
Researchers from the Icahn School of Medicine at Mount Sinai, The Broad Institute of MIT and Harvard, University of Pittsburgh School of Medicine, University of California-San Francisco, and Carnegie Mellon University have been awarded $7million from the National Institute of Mental Health to extend the work of the Autism Sequencing Consortium (ASC), an international research consortium established by these institutions in 2010 to collect and share samples and genetic data from individuals diagnosed with autism spectrum disorder (ASD).
The ASC was founded by Joseph D. Buxbaum, PhD, the G. Harold and Leila Y. Mathers Research Professor of Psychiatry, Neuroscience, and Genetics and Genomic Science at the Icahn School of Medicine at Mount Sinai and Director of The Seaver Autism Center for Research and Treatment at Mount Sinai. Launched with the initial support of the Beatrice and Samuel A. Seaver Foundation, the ASC aims to bring together investigators to share samples, data, and ideas without first publishing them in medical journals. No single lab has enough data to identify obscure genetic patterns that are scattered across thousands of genes, so this data-sharing collaboration is intended to make such research possible, thereby accelerating discovery.
In 2013, the National Institutes of Mental Health awarded $2.25 million to the ASC to expand the project to include data from more than 20,000 individuals over three years. The Consortium now includes more than 40 international groups and over 150 researchers, who have generated gene sequencing data from 29,000 individuals, making it the largest sequencing study to date in autism, and even in psychiatry. All shared data and analysis is hosted at Mount Sinai on a supercomputer called Minerva designed by Mount Sinai faculty, which enables joint analysis of large-scale data from many groups.
The new grant will extend the project through 2022 and expand the sample to include more than 50,000 individuals.
“Historically, the number of risk genes found has steadily increased with the number of patients studied, so it’s important that we continue to add patients to the data set,” says Dr. Buxbaum. “We are thrilled to receive this grant, which will enable our unique, collaborative research consortium to continue the work that is accelerating such important discovery.”
About the Seaver Autism Center for Research and Treatment at Mount Sinai
The Seaver Autism Center for Research and Treatment at Mount Sinai conducts progressive research studies aimed at understanding the multiple causes of ASD. The multidisciplinary team is composed of experts in the fields of genetics, molecular biology, model systems, neuroimaging, biomarkers, diagnosis, and experimental therapeutics who are dedicated to discovering the biological causes of ASD. The Center strives to develop innovative diagnostics and treatments for integration into the provision of personalized, comprehensive assessment and care for people with ASD. The Seaver Autism Center was founded through the generous support of the Beatrice and Samuel A. Seaver Foundation. For more information, visit www.seaverautismcenter.org.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Mount Sinai Researchers Discover Treatment Option for Rare Genetic Disorder
Aug 04, 2020 View All Press ReleasesMount Sinai Researchers: Why COVID-19 May Be Less Common in Children Than Adults
May 22, 2020 View All Press ReleasesGlobal Team Enables Child With a Fatal Genetic Disease to Recover
Jan 16, 2020 View All Press ReleasesIntegrated, Multi-“omic” Studies of Asthma Could Lead to Precision Treatment
Jul 02, 2019 View All Press ReleasesMount Sinai Researcher Bruce Gelb Named President-Elect of the American Pediatric Society
Apr 04, 2017 View All Press Releases